Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.

doi:10.1158/1078-0432.CCR-19-1209

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2020

Max Ma Xiaoju, Bendell Johanna C, Hurwitz Herbert I, Ju Christine, Lee John J, Lovejoy Alex, Mancao Christoph, Nicholas Alan, Price Richard, Sommer Nicolas, Tikoo Nalin, Yao Lijing, Yaung Stephanie J, Palma John F

Abstract excerpt

PURPOSE: We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy. EXPERIMENTAL DESIGN: The Sequencing Triplet With Avastin and Maintenance (STEAM) was a randomized, phase II trial investigating efficacy of bevacizumab (BEV) plus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Colon

Share to Induction Chemotherapy

Share to Intestinal Mucosa

Share to Kaplan-Meier Estimate

Share to Progression-Free Survival

Share to Rectum

Source

Open in PubMed

Identifiers

PMID: 32220893
DOI: 10.1158/1078-0432.CCR-19-1209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.PMID 32220893Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer.Semantic proximity Read ↗

Association of Emergence of New Mutations in Circulating Tumuor DNA During Chemotherapy With Clinical Outcome in Metastatic Colorectal CancerSemantic proximity Read ↗

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFRSemantic proximity Read ↗

Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients.Semantic proximity Read ↗

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.Semantic proximity Read ↗

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).Semantic proximity Read ↗

Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy.Semantic proximity Read ↗

Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.Semantic proximity Read ↗

Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic ResponseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.